Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma Carlos Iribarren, MD, MPH, PhD, Abdelkader Rahmaoui, MD, Aidan A. Long, MD, Stanley J. Szefler, MD, Mary S. Bradley, MS, Gillis Carrigan, PhD, MSc, Mark D. Eisner, MD, MPH, Hubert Chen, MD, MPH, Theodore A. Omachi, MD, MBA, Michael E. Farkouh, MD, MSc, Kenneth J. Rothman, DrPH Journal of Allergy and Clinical Immunology Volume 139, Issue 5, Pages 1489-1495.e5 (May 2017) DOI: 10.1016/j.jaci.2016.07.038 Copyright © 2016 The Authors Terms and Conditions
Fig 1 Identification and adjudication of CV and CBV events. MedDRA, Medical Dictionary for Regulatory Activities; SMQ, Standardized Medical Dictionary for Regulatory Activities Query. Journal of Allergy and Clinical Immunology 2017 139, 1489-1495.e5DOI: (10.1016/j.jaci.2016.07.038) Copyright © 2016 The Authors Terms and Conditions
Fig 2 Kaplan-Meier plot of time to first adjudicated study-emergent ATE SAE. Journal of Allergy and Clinical Immunology 2017 139, 1489-1495.e5DOI: (10.1016/j.jaci.2016.07.038) Copyright © 2016 The Authors Terms and Conditions
Fig E1 Patient use of OCSs during EXCELS, by treatment cohort and asthma severity. BL, Baseline. Journal of Allergy and Clinical Immunology 2017 139, 1489-1495.e5DOI: (10.1016/j.jaci.2016.07.038) Copyright © 2016 The Authors Terms and Conditions